Chief Business Officers: Shedding Light on Biotech’s Dealmakers
In an interview with Labiotech, Stephanie Bewick, Chief Business Officer at Destiny Pharma outlines her experiences of how a Chief Business Officer maximises their company’s commercial appeal and lands deals in the biotech industry, and what led her to the role.
In addition to helping patients, biotech companies need to focus on the commercial potential of their work. Stephanie Bewick began her career as an academic researcher before spending more than two decades in business development. She has occupied senior positions in biotech companies such as Summit Therapeutics as well as mid-sized pharma firms such as Mayne Pharma. In this time, she has negotiated and closed transactions ranging from the early research phase to late-stage clinical development.
